An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Terminated at 20 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by AbbVie · Observational
Strategic Considerations
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 9 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 2nd largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2022, is one of 10 observational ones, and was the 35th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Austria, France and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, France and 4 more countries
Ages 6 mo–17 yrs
AbbVie · Sites in India
Ages 18+
AbbVie · Sites in Colombia
Ages 18+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 7 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 62 across the 32 interventional studies, 113 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
5 of the studies in Leukemia, Myeloid, Acute by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05587049AbbVieA Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | 2026-11 |
| NCT04086264AbbVieIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | 2027-02 |
| NCT03987958AbbVieA Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study) | 2027-07 |
| NCT07044687AbbVieStudy to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult participants who are ineligible for intensive induction chemotherapy in Canada.
Venetoclax is a drug approved to treat Acute Myeloid Leukemia (AML). All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive induction chemotherapy will be enrolled. Around 200 participants will be enrolled in the study in approximately 15-20 sites in Canada.
Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 36 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 36 months.
Adult participants with acute myeloid leukemia (AML) treated with venetoclax per approved local label in Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated with Venetoclax in accordance with approved local label.
Overall Survival (OS)
OS as defined by number of days from start of treatment to the completion of treatment or death from any cause.
Time frame: Up to 36 Months
Change in Composite Complete Remission Rate
Composite Complete Remission Rate is defined as complete remission (CR) plus complete remission with incomplete hematologic recovery (CRi) as described by the modified International Working Group (IWG) criteria.
Time frame: Up to 36 Months
Event-Free Survival (EFS)
EFS as defined by number of days from start of treatment to the date of progressive disease, relapse from CR or CRi, treatment failure or death from any cause.
Time frame: Up to 36 Months
Percentage of Participants with Presence Transfusion Independence
Transfusion Independence is defined as at least 8 and/or 16 consecutive weeks without an Red Blood Cell (RBC) or platelet transfusion during the treatment period.
Time frame: Up to 36 Months
Number of Participants with Transfusions
Number of Participants with transfusions (red blood cells and platelets).
Time frame: Up to 36 Months
Number of Participants with Change in Venetoclax Dose
Number of participants with change in venetoclax dose.
Time frame: Up to 36 Months
Number of Participants with Change in Other Medications
Number of participants with change in other medications.
Time frame: Up to 36 Months
Venetoclax Administration Setting
Venetoclax administration setting (in-patient vs. out-patient vs. at home).
Time frame: Up to 36 Months
Number of Hospital Admission
Number of hospital admission.
Time frame: Up to 36 Months
Number of Participants with Change in use of Antiinfectives
Number of participants with change in use of antiinfectives.
Time frame: Up to 36 Months
Number of Participants with Change in Tumor Lysis Syndrome (TLS) Risk
Number of participants with change in TLS risk.
Time frame: Up to 36 Months
Occurrence of any Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
Time frame: Up to 36 Months
Plan to share: Undecided
Ran from Sep 2022 to primary completion in Aug 2026, 47 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Mar 2027 → Aug 2026 and completion Mar 2027 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Strategic Considerations
Strategic Considerations
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.